Scientific Article

Viability of Noncoplanar VMAT for liver SBRT compared with coplanar VMAT and beam orientation optimized $4\pi$ IMRT

Kaley Woods BS $^a$, Dan Nguyen BS $^a$, Angelia Tran BS $^a$, Victoria Y. Yu BS $^a$, Minsong Cao PhD $^a$, Tianye Niu PhD $^b$, Percy Lee MD $^a$, Ke Sheng PhD $^a$,*

$^a$ Department of Radiation Oncology, University of California, Los Angeles, California
$^b$ Translational Medicine Institute, Zhejiang University, Hangzhou, P.R. China

Received 2 November 2015; received in revised form 22 December 2015; accepted 23 December 2015

Abstract

Purpose: The $4\pi$ static noncoplanar radiation therapy delivery technique has demonstrated better normal tissue sparing and dose conformity than the clinically used volumetric modulated arc therapy (VMAT). It is unclear whether this is a fundamental limitation of VMAT delivery or the coplanar nature of its typical clinical plans. The dosimetry and the limits of normal tissue toxicity constrained dose escalation of coplanar VMAT, noncoplanar VMAT and $4\pi$ radiation therapy are quantified in this study.

Methods and materials: Clinical stereotactic body radiation therapy plans for 20 liver patients receiving 30 to 60 Gy using coplanar VMAT (cVMAT) were replanned using 3 to 4 partial noncoplanar arcs (nVMAT) and $4\pi$ with 20 intensity modulated noncoplanar fields. The conformity number, homogeneity index, 50% dose spillage volume, normal liver volume receiving $>15$ Gy, dose to organs at risk (OARs), and tumor control probability were compared for all 3 treatment plans. The maximum tolerable dose yielding a normal liver normal tissue control probability $<1\%$, $5\%$, and $10\%$ was calculated with the Lyman-Kutcher-Burman model for each plan as well as the resulting survival fractions at 1, 2, 3, and 4 years.

Results: Compared with cVMAT, the nVMAT and $4\pi$ plans reduced liver volume receiving $>15$ Gy by an average of 5 cm$^3$ and 80 cm$^3$, respectively. $4\pi$ reduced the 50% dose spillage volume by $\sim23\%$ compared with both VMAT plans, and either significantly decreased or maintained OAR doses. The $4\pi$ maximum tolerable doses and survival fractions were significantly higher than both cVMAT and nVMAT ($P < .05$) for all normal liver normal tissue control probability limits used in this study.

Conclusions: The $4\pi$ technique provides significantly better OAR sparing than both cVMAT and nVMAT and enables more clinically relevant dose escalation for tumor local control. Therefore, despite the current accessibility of nVMAT, it is not a viable alternative to $4\pi$ for liver SBRT.
Introduction

Liver cancer is responsible for over 600,000 deaths each year, according to the American Cancer Society, making it a leading cause of cancer deaths worldwide. Although surgical resection is considered the primary treatment option for hepatocellular carcinoma and oligometastases, 80% to 90% of patients present with unresectable tumors, which are treated with modalities including radiation therapy. Conventionally fractionated radiation therapy has shown ineffective to achieve local control, but stereotactic body radiation therapy (SBRT), with the delivery of fewer high-dose fractions, is a more effective treatment for patients with eligible conditions, which typically include inoperable liver tumors under the size of 6 cm and certain liver function criteria. The success of SBRT is largely owed to the higher biological effective doses (BED) as well as normal tissue sparing afforded by improved dose conformity from recent advances in radiation physics.

Volumetric modulated arc therapy (VMAT) is a practical and effective delivery technique for liver SBRT, and has demonstrated normal tissue sparing and dose conformity superior to coplanar intensity modulated radiation therapy (IMRT). Although the incorporation of non-coplanar beams has improved normal tissue sparing in liver IMRT studies, typical clinical VMAT liver plans are still coplanar, consisting of a pair of (clockwise and counterclockwise) arcs using collimators with 90° rotational offset. To gain dose conformity and liver sparing, manually selected noncoplanar VMAT has been clinically used, but its benefits have not been quantified. Meanwhile, methods for the automatic selection of noncoplanar IMRT beams and optimized fluence maps have been developed for treatment sites including liver SBRT. Two separate groups have shown that by optimizing noncoplanar beam orientation selection, superior dosimetry to coplanar VMAT can be attained. In this study, we refer to the beam orientation optimized noncoplanar IMRT plans as “4π static” because of the maximum of 4π steradian angles that can be used for noncoplanar beam orientation optimization. The usable angles are typically smaller than 4π because of collision concerns and couch pedestal occlusion. Because the delivery efficiency of noncoplanar IMRT plans is considered lower than that of VMAT without the use of automation, a function unavailable to most clinics, 1 important question is whether manually selected noncoplanar VMAT, which is the only clinically available method to incorporate these arcs, can offer dosimetry superior to coplanar VMAT while maintaining the advantage of clinical availability and efficiency. The purpose of this study is therefore to quantify and compare the dosimetry of these planning methods for liver SBRT.

Methods and Materials

Coplanar VMAT plans

Under institutional review board approval, treatment plans including computed tomography, dose, and contours were obtained for 20 liver SBRT patients (Table 1). These patients were treated with VMAT plans (RapidArc, Eclipse Treatment Planning System Version 10, Varian), typically consisting of 2 full coplanar arcs (cVMAT) with 90° collimator angle offset. The few original plans that included 1 partial noncoplanar arc were reoptimized in Eclipse with 1 full coplanar arcs to set a uniform baseline.

Noncoplanar VMAT plans

These clinical plans were replanned in Eclipse with 3 to 4 manually selected partial noncoplanar arcs (nVMAT), as shown in Figure 1 (middle), with collimator angle offsets between 45° and 135°. The average total arc length for the 20 nVMAT plans was 553°. These arcs were empirically chosen to maximize noncoplanar angles while avoiding collision. Each plan typically consisted of 1 arc with a 0° couch rotation, 2 arcs with an average couch rotation of ±21° (−40° to +35° range), and for a few patients with tumors located near the mid-sagittal plane, 1 arc with a nearly perpendicular couch pitch (86° on average). The optimization objectives were set up to minimize dose to liver, kidneys, spinal cord, and stomach, with the highest priority placed on the normal liver dose. All plans were normalized to deliver 100% of the prescribed dose to 95% of the planning target volume (PTV), and PTV hot spots were limited to those of the respective coplanar plans. A source-to-axis distance of 100 cm was maintained for all plans.

4π static plans

The first step in the 4π static optimization process, the details of which have been previously reported, is to eliminate any beams out of the 1162 beam 4π static solid angle space that would cause collisions between the gantry and couch or patient. From the remaining beams, an integrated beam orientation and fluence map optimization
is performed using a greedy column generation method. Briefly, the remaining candidate beams were subdivided into $5 \times 5 \text{ mm}^2$ beamlets and the dose distribution matrices of each beamlet were calculated using collapsed-cone convolution/superposition codes and 6-MV x-ray polyenergetic kernels with heterogeneity corrections. The dose calculation model was tuned to match 6-MV machine commissioning data. The dose calculation resolution was $2.5 \times 2.5 \times 2.5 \text{ mm}^3$. The first-order derivative of the quadratic cost function with each additional beam from the candidate pool was evaluated and the beam that contributed most was kept. The process was iteratively performed until the desired number of beams was selected. Full fluence map optimization was performed after each beam selection. Although the cost function value did not converge, the dosimetric gains with more than 20 beams were modest. Considering a balance between plan deliverability and plan quality, in this study, 20 beams were selected with the static algorithm for each patient, such as those in Figure 1 (right), the gantry and couch angles for each beam were imported into Eclipse to develop a clinically deliverable treatment plan using identical dose calculation engine as the VMAT plans. The organs at risk (OAR) constraints, plan normalization, source-to-axis distance, and PTV hotspots matched those described earlier for the nVMAT plans.

### Additional notes on the optimization implementation

For each plan optimization, dose constraints were placed on the liver, kidney, spinal cord, and stomach. When necessary, additional optimization constraints were placed on other OARs such as the bowel or heart, depending on the location of the tumor. Although the constraints and penalties were initially the same for each, these parameters were adjusted throughout the optimization process to further reduce OAR doses for all

### Table 1  Patient data

| Diagnosis                                | Prescription dose (Gy) | Fractions | PTV (cm³) | Normal liver volume (cm³) | Liver volume (cm³) |
|------------------------------------------|------------------------|-----------|-----------|--------------------------|-------------------|
| 1 Metastatic esophageal cancer           | 60                     | 5         | 53.3      | 1491.0                   | 1544.5            |
| 2 Metastatic squamous cell carcinoma     | 60                     | 5         | 64.9      | 2169.9                   | 2234.7            |
| 3 Metastatic adenocarcinoma of the lung  | 60                     | 5         | 46.7      | 1194.2                   | 1239.0            |
| 4 Metastatic colorectal cancer           | 60                     | 5         | 35.6      | 1168.6                   | 1187.5            |
| 5 Metastatic colon cancer                | 60                     | 5         | 59.2      | 1404.7                   | 1454.3            |
| 6 Metastatic colorectal cancer           | 50                     | 5         | 123.0     | 1324.1                   | 1447.1            |
| 7 Metastatic uterine carcinosarcoma      | 50                     | 5         | 35.1      | 1768.8                   | 1803.8            |
| 8 Metastatic transitional cell from the kidney | 60                  | 5         | 30.2      | 1241.2                   | 1270.1            |
| 9 Metastatic colon cancer                | 60                     | 5         | 179.0     | 1752.7                   | 1909.4            |
| 10 Hepatocellular carcinoma              | 36                     | 3         | 54.4      | 1133.4                   | 1187.9            |
| 11 Metastatic colon cancer               | 60                     | 5         | 88.4      | 1302.7                   | 1391.1            |
| 12 Metastatic prostate adenocarcinoma    | 60                     | 5         | 10.5      | 1442.7                   | 1453.3            |
| 13 Metastatic cholangiocarcinoma         | 40                     | 5         | 48.8      | 1837.0                   | 1837.0            |
| 14 Metastatic high-grade cholangiocarcinoma | 48                   | 3         | 19.4      | 1027.0                   | 1047.8            |
| 15 Cholangiocarcinoma                   | 40                     | 5         | 88.7      | 1787.0                   | 1852.0            |
| 16 Cholangiocarcinoma                   | 40                     | 5         | 67.0      | 2517.6                   | 2577.3            |
| 17 Cholangiocarcinoma                   | 40                     | 5         | 141.8     | 1809.6                   | 1926.6            |
| 18 Metastatic primitive germ cell tumor  | 30                     | 5         | 192.9     | 3342.8                   | 3346.1            |
| 19 Metastatic gall bladder small-cell carcinoma | 60                  | 5         | 109.4     | 1533.5                   | 1616.2            |
| 20 Metastatic bile duct adenocarcinoma   | 50                     | 5         | 57.3      | 1107.8                   | 1148.6            |

PTV, planning target volume.

---

**Figure 1**  Beam geometry comparison for a typical liver stereotactic body radiation therapy case. Beam orientation is shown for the coplanar volumetric modulated arc therapy (VMAT) plan (left), 3 to 4 noncoplanar partial arcs (center), and 20 noncoplanar, optimized beams (right).
techniques. Because plan optimizations with Eclipse depend on both the sequence of the planning parameters used along with the process and the timing of when they are used, maintaining a single set of constraints and penalties generally would result in poorer plan quality. Instead, the objectives for each plan were pushed as hard as possible to reduce OAR doses, particularly to the normal liver, while maintaining acceptable PTV coverage (typically between 2 and 4 runs).

**Plan comparison**

The cVMAT, nVMAT, and 4π static plans were evaluated by comparing various metrics of normal tissue sparing. The minimum dose to 98% of the PTV (D98%) was compared among the 3 plans to evaluate any underdosage to the target. The conformity of each plan was evaluated by the conformity number (CN), defined by van’t Riet et al as

\[
CN = \frac{TV_{R1}}{TV} \times \frac{TV_{R1}}{V_{R1}},
\]

where \(TV_{R1}\) is the target volume covered by the prescription isodose, \(TV\) is the target volume, and \(V_{R1}\) is the volume of the prescription isodose.\(^{1,3}\) \(R_{50}\), defined as the ratio of the 50% isodose volume to the PTV, was used to evaluate the dose gradient outside the PTV. The homogeneity index was also calculated as \(1 + (D2\% - D98\%)/ pulsating dose)\). The normal liver volume receiving >15 Gy (VL\(\text{cTV}15\)) was quantified to assess normal tissue dose, as were the mean and maximum doses to OARs.

A radiobiological modeling study was performed to compare the probabilities of tumor control, normal tissue complication, and patient survival. The tumor control probability (TCP) was first calculated for each plan. Because TCP calculation parameters vary widely between studies and for different tumor types,\(^{14,15}\) and because a variety of tumor origins were included in this study, high tumor radioreistance was assumed for the parameter selection (\(\alpha = 0.2\ \text{Gy}^{-1}, \ \beta = 10\ \text{Gy}\) for a conservative TCP estimate. The Kutcher-Burman dose-volume histogram (DVH) reduction scheme\(^{16}\) was used to calculate the normal liver effective volume, the percentage of the normal liver volume that, if irradiated uniformly to the prescription dose, would give the same normal tissue complication probability (NTCP) as the nonuniform dose distribution. The effective volume was then used to calculate the normal liver NTCP using the Lyman model.\(^{17}\) The Lyman-Kutcher-Burman (LKB) NTCP model parameters from Dawson et al were used (TD\(50 = 45.8\ \text{Gy}\) [metastases], TD\(50 = 39.8\ \text{Gy}\) [primary tumors], \(n = 0.97, m = 0.12\)). Because these parameters were obtained from fractionated treatment plans, the SBRT plans in this study were normalized to 1.5 Gy per fraction using \(\alpha/\beta = 2.5\ \text{Gy}\).\(^{19}\)

**Dose escalation**

The prescription dose for each plan was escalated (or reduced) to the maximum tolerable dose (MTD) yielding a normal liver NTCP below the desired limit. The number of fractions for the clinical plans was maintained, with an escalated dose per fraction. In this study, MTDs for NTCP limits of 1%, 5%, and 10% were calculated. The BED for each MTD was determined by

\[
BED = Nd + \frac{N}{\alpha/\beta} \left( \ln \left( \frac{d}{T} \right) \right)^2 - \ln \left( \frac{d}{T} \right) T
\]

with number of fractions \(N\), dose per fraction \(d\), total treatment time \(T\), \(\alpha = 0.01, \alpha/\beta = 15\), and tumor doubling time \(T_d = 120\ \text{days}\) from Tai et al.\(^{20}\) The survival model developed by Tai et al was used to predict the survival rates (SR) for each plan based on the BED:

\[
SR(D, d, \tau) = 1 - \frac{1}{\sqrt{2\pi}} \int_{-\infty}^{t} e^{-\frac{x^2}{2}} \, dx
\]

where \(D\) is the prescription dose, \(\tau\) is the elapsed time since treatment, \(\delta\) describes the tumor growth rate, \(K_0\) is the initial number of tumor clonogens, \(K_{50}\) is the critical number of tumor clonogens corresponding to death in 50% of patients, \(\sigma_2\) is the Gaussian width for the critical clonogen number distribution, and \(\gamma = \ln(2)/T_d\). The fitting parameters from Tai et al are \(K_{50}/K_0 = 2.03, \sigma_2/K_0 = 0.65, \delta = 0.2\).\(^{20}\) Survival fractions at 1, 2, 3, and 4 years were calculated for each plan before and after dose escalation.

**Results**

**Plan comparison**

The average dose statistics for each plan type, using paired, 2-tailed \(t\) tests, are given in Table 2. On average, the nVMAT plans delivered higher kidney doses than the cVMAT plans and lower doses to the other OARs, but the
only statistically significant difference was an increased V50%. However, there were large improvements with 4π static compared with both VMAT techniques. The mean dose to the normal liver was significantly lower with the 4π static plan, and the liver volume receiving >15 Gy was reduced from the cVMAT and nVMAT plans by 79.8 cm³ and 74.8 cm³, respectively (>32%). Although nVMAT enabled reductions in maximum stomach and spinal cord doses (compared with cVMAT) of approximately 2% and 14%, respectively, 4π static reduced these doses by 32% and 40%. The homogeneity index and CN values were similar for all plans. The individual dosimetric parameter comparison is shown in Figure 2. Consistent reduction in the R50 from cVMAT to 4π static was observed for all patients and the reduction is correlated to that of liver V15 and mean liver dose. In comparison, R50 of nVMAT slightly increased from cVMAT, indicating no improvement in the dose compactness.

These reductions in OAR dose are evident in the DVHs in Figure 3 (top). Additionally, the 4π static technique reduced the 50% dose spillage volume by >22% compared with both VMAT plans. The major reduction in 50% isodose volume with the 4π static technique is evident in the dose washes in Figure 3 (bottom). Although the dose washes show less low dose spillage for the nVMAT plan than the cVMAT plan, the isodose volume above 15 Gy is very similar. There was a statistically significant difference between the mean cVMAT and 4π static PTV D98% doses, but only by 0.2 Gy.

The average TCP values (calculated with the LKB model), given in Table 3, were very similar for nVMAT and cVMAT plans and slightly (~1.1%) lower for 4π static. Although the optimization constraints on the maximum PTV dose were relaxed, 4π static plans still tend to result in more homogeneous PTV doses, as seen in the DVH in Figure 2 (top), and slightly lower TCP.

The average normal liver effective volume was very similar for the VMAT plans, but was significantly reduced with 4π static by >15%. The resultant NTCP was therefore also much lower, with reductions of 69% from cVMAT and 73% from nVMAT.

### Dose escalation

The results of the dose escalation are given in Table 4. For every NTCP limit, 4π static enabled significantly higher average MTDs than both cVMAT and nVMAT. The escalated doses for 4π static were approximately 20% and 14% higher than those for cVMAT and nVMAT, respectively. The corresponding BEDs for 4π static were higher than cVMAT and nVMAT for every NTCP limit by about 39% and 19%, respectively, with a statistically significant difference between 4π static and cVMAT at the 5% level (paired, 2-tailed t test). The average MTD and BED for nVMAT were higher than cVMAT for every NTCP limit, but not statistically significant at the 5% level.

The average survival fractions at 1, 2, 3, and 4 years for each NTCP limit (1%, 5%, and 10%) showed a statistically significant increase for the 4π static plans compared with both VMAT plans, as shown in Figure 4. These improvements were most significant for the 4π static 4-year survival fraction, which was more than 7% higher than both VMAT plans at the 10% and 5% NTCP limits and more than 9% higher at the 1% NTCP limit. Even for conservative treatments allowing for only a 1% probability of liver complications, 4π static technique enabled an average 4-year survival fraction of 86%. This increased to 93% when a 10% NTCP was tolerated.

### Delivery time

The delivery time of 2 arc cVMAT for SBRT treatment was estimated as 5 to 7 minutes. The time increased by an additional 1 to 3 minutes for nVMAT, depending on whether remote couch rotation was used. Delivery of

---

**Table 2** Average dose statistics for coplanar VMAT, noncoplanar VMAT, and 4π plans for all 20 patients

| Plan type | OAR doses (Gy) | PTV D98% (Gy) | VL_{5-15} (cm³) | V50% (cm³) | R50 | HI | CN |
|-----------|----------------|---------------|-----------------|------------|-----|----|----|
| cVMAT     |                |               |                 |            |     |    |    |
| nVMAT     |                |               |                 |            |     |    |    |
| 4π        |                |               |                 |            |     |    |    |
| Left kidney (mean) | 1.42 (2.4) | 2.04 (2.4) | 7.07 (2.6) | 11.15 (6.7) | 6.69 (3.2) | 1.51 (0.6) |
| Right kidney (mean) | 2.09 (2.5) | 2.09 (2.5) | 6.97 (2.8) | 10.95 (10.0) | 5.74 (4.0) | 1.51 (0.6) |
| Normal liver (mean) | 0.82 (1.2) | 1.70 (1.4) | 6.01 (2.3) | 7.58 (6.3) | 4.00 (3.7) | 1.46 (0.6) |
| Stomach (maximum) | 49.62 (9.7) | 233.7 (122.3) | 287.5 (213.4) | 3.66 (0.4) | 0.11 (0.03) | 0.94 (0.03) |
| Cord (maximum) | 1.46 (2.1) | 2.09 (2.5) | 6.97 (2.8) | 10.95 (10.0) | 5.74 (4.0) | 1.51 (0.6) |
| Body (mean) | 1.46 (2.1) | 2.09 (2.5) | 6.97 (2.8) | 10.95 (10.0) | 5.74 (4.0) | 1.51 (0.6) |

*Significantly different from 4π with \( P < .05 \) (paired, 2-tailed t test).

*Significantly different from 4π and other VMAT plan type with \( P < .05 \) (paired, 2-tailed t test).
the 4π treatment with 20 beams can take 45 minutes with manual couch rotation and translation. A significant portion of the time was used by the therapist to enter and exit the shielded vault. Consequently, the time can be reduced to 12 minutes with automated delivery, in line with the nVMAT delivery time.

Discussion

The success of SBRT is largely attributed to the improved physical dose conformity enabled by recent advances in radiation therapy techniques, including intensity modulated radiation therapy, image-guided radiation therapy, and volumetric modulated arc therapy. A previous study showed that tumor local control can benefit from further dose escalation, but is limited by normal tissue toxicity.

Experience from intracranial radiosurgery suggests that an effective way to achieve a steeper dose gradient outside the tumor is by adding non-coplanar beams and arcs. The usefulness of noncoplanar beams in SBRT has been far less clear. R50 has been commonly used to evaluate the dose compactness in SBRT treatment, the minimization of which leads to more effective SBRT. Lung Radiation Therapy Oncology Group protocols recommend using either noncoplanar static or coplanar arc beams to achieve the R50 dosimetric goal. Lim et al showed that compared against coplanar plans, lower R50 could be achieved in 81% of patients when noncoplanar

Figure 2 Individual patient dosimetric results comparison. CI, confidence interval; cVMAT, coplanar volumetric modulated arc therapy; L, left; max, maximum; nVMAT, noncoplanar volumetric modulated arc therapy; R, right.
beam arrangement was employed. However, in a different lung study, no dosimetric improvements were found comparing coplanar and noncoplanar IMRT plans. In the case of liver radiation therapy, it was found that the advantage of using noncoplanar beams can be matched by coplanar plans with a large number of beams. Noncoplanar VMAT has been used on an ad hoc basis in liver SBRT with the expectation that these arcs should improve normal organ sparing without quantification of the dosimetric improvement.

In this study, we compared 3 clinically deliverable planning methods for liver SBRT. Our study shows that the incorporation of this type of arrangement of noncoplanar VMAT arcs offered modest dosimetric gains over coplanar VMAT. However, by fully using the freedom of the noncoplanar beam geometry solution space and automated beam orientation selection, the $4\pi$ static technique achieved major reductions in the dose to OARs, particularly the normal liver, stomach, and spinal cord, as well as a much more compact dose distribution.

### Table 3

| Plan Type | TCP (%) | V_{eff} (%) | NTCP (%) |
|-----------|---------|-------------|----------|
| cVMAT     | 7.37% (11.5%) | 13.79% (5.2%) | 5.29% (18.8%) |
| nVMAT     | 7.40% (11.1%) | 14.00% (5.9%) | 6.22% (22.2%) |
| $4\pi$    | 6.25% (9.7%) | 11.63% (4.35%) | 1.65% (6.3%) |

cVMAT, coplanar volumetric modulated arc therapy; nVMAT, noncoplanar volumetric modulated arc therapy; V_{eff}, effective volume.

a The mean NTCP is drastically increased by 2 outlying patients, without which the mean NTCP values are 0.06%, 0.53%, and 0.02% for cVMAT, nVMAT, and $4\pi$, respectively.

b Significantly different from $4\pi$ plans with $P < .05$ (paired, 2-tailed $t$ test).
There are several reasons for the minimal plan quality improvement from nVMAT over cVMAT. First, in practice, the number of VMAT arcs is limited. Because of the continuity of the arcs, large noncoplanar angles are prohibited to avoid collision. This is different from intracranial stereotactic radiation surgery, where a large noncoplanar beam solution space can be nearly uniformly sampled and included. It has been shown that the inclusion of small noncoplanar arc angles in a rotational IMRT system does not significantly improve the plan quality.28 Second, selection of noncoplanar arcs is unintuitive to the planner. It is difficult, if not impossible, for a human operator to optimally select segments of noncoplanar arcs, considering the freedoms of arc lengths and locations. One way to overcome this limitation is by optimizing the noncoplanar arc selection. However, a method to globally search the noncoplanar arc trajectories, or “4π arc,” is unavailable. Papp et al29 reported a noncoplanar arc optimization method based on static beam orientation optimization and then use these beams to anchor noncoplanar segments. However, this method does not promise arcs between the anchoring beams are optimal. Furthermore, the method would result in arcs that require simultaneous couch and gantry rotation and are undeliverable in the clinical mode. Both limitations are effectively overcome using 4π static planning, where the collision-free beam geometry solution space is individually mapped and the beam orientations are optimized. Therefore, even though nVMAT is currently available and more efficient to deliver, it is not a reasonable substitution for 4π static.

A major difference between the current study and the previously published report of using 4π static for liver SBRT10 is that the liver SBRT plans are generated in Eclipse using identical dose calculation engine to ensure an unbiased comparison. Compared with the previous study, the liver VL_{>15} was further reduced by an additional ~30 cm$^3$ to 80 cm$^3$. This increased normal tissue sparing is crucial for liver SBRT because it enables escalation of the prescription dose to the PTV without further complications from high doses to normal tissue. Our dose escalation study showed that for the same normal liver complication probability, prescription doses delivered with the 4π static technique could be

### Table 4

|       | 1% NTCP | 5% NTCP | 10% NTCP |
|-------|---------|---------|----------|
|       | MTD (Gy) | BED (Gy) | MTD (Gy) | BED (Gy) | MTD (Gy) | BED (Gy) |
| cVMAT | 76.80±(27.6) | 170.40±(97.8) | 85.51±(30.7) | 202.70±(117.6) | 90.14±(32.4) | 220.94±(129.0) |
| nVMAT | 80.63±(37.7) | 198.32±(177.7) | 89.76±(41.6) | 236.78±(215.5) | 94.65±(43.8) | 258.67±(237.4) |
| 4π    | 91.98±(36.2) | 235.80±(164.8) | 102.43±(40.3) | 281.91±(199.8) | 107.99±(42.5) | 308.08±(219.8) |

cVMAT, coplanar volumetric modulated arc therapy; NTCP, normal tissue complication probability; LKB, Lyman-Kutcher-Burman; MTD, maximum tolerated dose; nVMAT, noncoplanar volumetric modulated arc therapy. 

* Significantly different from 4π plans with $P < .05$ (paired, 2-tailed t test).

---

**Figure 4** Average survival predicted with the model from Tai et al20 for the maximum tolerable doses yielding 1%, 5%, and 10% normal liver NTCPs. All fractions for nVMAT and cVMAT were significantly different than 4π static at the 5% significance level (paired, 2-tailed t test). cVMAT, coplanar volumetric modulated arc therapy; NTCP, normal tissue control probability; nVMAT, noncoplanar volumetric modulated arc therapy; PTV, planning target volume.
escalated 20% higher than cVMAT plans and 14% higher than nVMAT plans, leading to significant increases in predicted survival fractions.

Improved liver tumor motion management can be combined with 4π static radiation therapy for additional dosimetric gains, but the gain may be less significant. For example, Velec et al.\(^3\) showed that by reducing the PTV volume using the mean respiratory position, the isotropy PTV dose can be escalated by 4 Gy, a moderate number compared to the dose escalation using 4π static.

**Conclusions**

4π static radiation therapy using optimized noncoplanar beams significantly reduces normal liver doses that can facilitate safe tumor dose escalation. Despite its clinical availability, VMAT using noncoplanar arcs is not a viable replacement of 4π static radiation therapy for compact dose liver SBRT.

**References**

1. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis. *Cancer*. 2011;117:4060-4069.
2. Lawrence TS, Robertson JM, Anscher MS, et al. Hepatic toxicity resulting from cancer treatment. *Int J Radiat Oncol Biol Phys*. 1995;31:1237-1248.
3. Wahl DR, Stenmark MH, Tao Y, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma [e-pub ahead of print]. *J Clin Oncol*. Accessed January 10, 2016.
4. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. *Cancer*. 2012;118:3191-3198.
5. Rushoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol*. 2009;27:1572-1578.
6. Mornex F, Girard N, Merle P, et al. [Tolerance and efficacy of conformal radiotherapy for hepatocellular carcinoma in cirrhotic patients. Results of the French RTFI phase II trial]. *Cancer Radiother*. 2005;9:470-476.
7. Wang PM, Hsu WC, Chung NN, et al. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. *Radiat Oncol*. 2014;9:18.
8. Thomas E, Chapet O, Kessler ML, et al. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. *Int J Radiat Oncol Biol Phys*. 2005;62:571-578.
9. de Pooter JA, Mendez Romero A, Wunderink W, et al. Automated non-coplanar beam direction optimization improves IMRT in SBRT of liver metastasis. *Radiother Oncol*. 2008;88:376-381.
10. Dong P, Lee P, Ruan D, et al. 4pi non-coplanar liver SBRT: A novel delivery technique. *Int J Radiat Oncol Biol Phys*. 2012;85:1360-1366.
11. Yu VY, Tran A, Nguyen D, et al. The development and verification of a highly accurate collision prediction model for automated noncoplanar plan delivery. *Med Phys*. 2015;42:6457-6467.
12. Romeijn HE, Ahuja RK, Dempsey JF, Kumar A. A column generation approach to radiation therapy treatment planning using aperture modulation. Available at: http://dx.doi.org/10.1137/040606612. Accessed January 10, 2016.
13. van’t Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W. A conformation number to quantify the degree of conformity in brachytherapy and external beam irradiation: Application to the prostate. *Int J Radiat Oncol Biol Phys*. 1997;37:731-736.
14. Deacon J, Peckham MJ, Steel GG. The radiobiology of human tumors and the initial slope of the cell survival curve. *Radiother Oncol.*, 1984;2:317-323.
15. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. *Int J Radiat Oncol Biol Phys*. 1985;11:1699-1707.
16. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. *J Radiat Oncol Biol Phys*. 1989;16:1623-1630.
17. Lyman JT. Complication probability as assessed from dose-volume histograms. *Radiat Res Suppl*. 1985;8:S13-S19.
18. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. *Int J Radiat Oncol Biol Phys*. 2002;53:810-821.
19. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver SBRT. *Acta Oncol*. 2006;45:856-864.
20. Tai A, Erickson B, Khater LI, Li XA. Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation. *Int J Radiat Oncol Biol Phys*. 2008;70:900-907.
21. Podgorsak EB, Pike GB, Olivier A, Pla M, Souhami L. Radiotherapy with high energy photon beams: A comparison among techniques. *Int J Radiat Oncol Biol Phys*. 1989;16:857-865.
22. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. *J Thoracic Oncol*. 2007;2:S101-S112.
23. Yang J, Fowler JF, Lamond JP, Lanciano R, Feng J, Brady LW. Red shell: Defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2010;77:903-909.
24. Timmerman R, Kavanagh B. Stereotactic Body Radiation Therapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
25. Dreycke S, Van Duyse B, De Gersem W, De Wager C, De Neve W. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer. *Radiother Oncol*. 1997;45:253-261.
26. Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2007;67:735-741.
27. Hsieh CH, Liu CY, Shueng PW, et al. Comparison of coplanar and noncoplanar intensity-modulated radiation therapy and helical tomotherapy for hepatocellular carcinoma. *Radiat Oncol*. 2010;5:40.
28. Yang W, Jones R, Lu W, et al. Feasibility of non-coplanar tomotherapy for lung cancer stereotactic body radiation therapy. *Technol Cancer Res Treat*. 2011;10:307-315.
29. Papp D, Bortfeld T, Unkelbach J. A modular approach to intensity-modulated arc therapy optimization with noncoplanar trajectories. *Phys Med Biol*. 2015;60:5179-5198.
30. Velec M, Moseley JL, Dawson LA, Brock KK. Dose escalated liver stereotactic body radiation therapy at the mean respiratory position. *Int J Radiat Oncol Biol Phys*. 2014;89:1121-1128.